
Sign up to save your podcasts
Or


Send us Fan Mail
Can a machine discover a cure faster than a scientist? Welcome to the revolutionary world of Recursion Pharmaceuticals, the pioneering TechBio company determined to solve biology using AI and industrial automation.
In this deep-dive, we explore how Recursion replaced slow, human-biased research with the Recursion OS, a closed-loop platform that generates massive, proprietary biological data. Learn about the company's bold vision, from the crucial $50 million NVIDIA investment and the strategic merger with Exscientia to the immense computational power of the Boltz-2 supercomputer. We analyze their pipeline progress in oncology and rare diseases, discuss the challenges of high cash burn (like the recent pipeline streamlining in November 2025), and examine their critical partnerships with giants like Roche/Genentech. Discover why Recursion is leading the charge to build the digital "Map of Biology and Chemistry" to cut drug discovery time from a decade to mere years.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Recursion #TechBio #AIDrugDiscovery #NVIDIA #Biotech #PharmaInnovation #MachineLearning #OmicsData #Genomics #RecursionOS #PetriDishPerspectives #BiotechPodcast
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
Welcome to your essential overview of the global biotech and pharmaceutical landscape for November 2025!
This month was dominated by a surge in M&A activity, with high-profile bidding wars!Â
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!
https://linktr.ee/maneadkhin
#PetriDishPerspectives #BiotechNews #PharmaNews
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
Unlock the future of immunotherapy. For decades, traditional antibody drugs were limited to tagging a single target. Now, meet the Bispecific Antibody (BsAb): a revolutionary molecule engineered to simultaneously grab two different targets, acting as a molecular "handcuff" to drag your immune system's most powerful killer, the T cell, directly to the cancer cell.
In this episode, we trace the incredible scientific journey of BsAbs: from the manufacturing failure of the Quadroma Problem to the engineering solution of the "Knobs-into-Holes" strategy and the super-potent BiTE format. You'll hear how drugs like Blinatumomab have become "off-the-shelf" T-cell therapies, transforming treatment for blood cancers. We also explore the challenges of managing side effects like Cytokine Release Syndrome (CRS) and the promise of using BsAbs to conquer solid tumors. If you want to understand the sharp edge of modern cancer research, this is a must-listen.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#BispecificAntibodies #Immunotherapy #CancerResearch #BiotechBreakthrough #Oncology #TCellEngager #SciencePodcast #DrugDiscovery #PetriDishPerspectives
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
In this episode of Petri Dish Perspectives:, we dive into one of the most dramatic biotech stories of the decade: the rise of Metsera, the VC-backed obesity startup that triggered a rare billion-dollar bidding war between two pharma giants, Pfizer and Novo Nordisk.
We explore how Metsera quietly emerged from Flagship’s venture creation engine, how its science positioned it as a next-generation competitor in the GLP-1 era, and why its pipeline, from injectable GLP-1s to amylin analogs, became one of the most sought-after assets in metabolic disease. You’ll learn how the bidding unfolded, what the acquisition means for obesity therapeutics, and why Pfizer ultimately paid nearly $10 billion to secure the company.
If you want to understand obesity biotech, GLP-1 strategy, and how a young startup can reshape Big Pharma’s roadmap, this is the episode to hear.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #Metsera #Pfizer #NovoNordisk #GLP1 #ObesityDrugs #BiotechPodcast #FlagshipPioneering #DrugDevelopment #PharmaNews #LifeSciences
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
In this episode of Petri Dish Perspectives, we dive into the untold story of Charles River Laboratories, the quiet giant behind nearly every major drug you’ve ever heard of.
From its origins on the banks of Massachusetts’ Charles River, where Dr. Henry Foster began breeding lab rats to support post-war research, to its evolution into a global scientific infrastructure company, Charles River has shaped the very foundation of modern drug development.
We’ll explore how a small animal breeding business became the unseen force driving pharmaceutical innovation, the company’s expansion under James Foster, and its deep involvement in gene therapy, biologics, and vaccine testing.
You’ll also hear about the complex ethical landscape Charles River navigates balancing innovation and regulation in a world demanding both faster cures and higher transparency.
By the end of this episode, you’ll understand why behind every breakthrough, from oncology to rare diseases, there’s often a quiet partner ensuring that science moves safely from lab bench to bedside.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead dives into the remarkable story of Regeneron Pharmaceuticals, from its humble beginnings in Tarrytown to becoming one of the world’s leading biotech innovators.
Discover how founders Leonard Schleifer and George Yancopoulos turned early failure into scientific triumph with breakthrough drugs like Eylea, Dupixent, and the COVID-19 antibody cocktail that changed the global response.
We explore how Regeneron built a culture rooted in pure science, balanced innovation with controversy, and redefined what it means to be a biotech powerhouse in a pharma-dominated world.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#PetriDishPerspectives #BiotechUnleashed #Regeneron #LeonardSchleifer #GeorgeYancopoulos #Eylea #Dupixent #VelocImmune #BiotechPodcast #LifeSciences #PharmaInnovation #DrugDiscovery #COVID19 #HealthcareInnovation #BiotechStorytelling
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
What if the cure for cancer or the key to mental health, wasn’t hidden in a new drug, but in data itself? In this episode of Petri Dish Perspectives, we uncover the story of Tempus AI, the company turning raw medical information into lifesaving insight.
Founded by Eric Lefkofsky, the entrepreneur behind Groupon, Tempus began as a deeply personal mission to bring clarity to cancer care. Today, it’s one of the most advanced AI-driven healthcare platforms in the world, combining genomics, clinical data, and machine learning to help doctors make better, faster decisions.
We explore how Tempus built one of the largest clinico-genomic databases in existence, its bold leap into psychiatry, cardiology, and COVID research, and how it went public to cement its place at the forefront of precision medicine.
If you’ve ever wondered how AI is reshaping healthcare from the inside out, this episode is your front-row seat.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#PetriDishPerspectives #BiotechUnleashed #TempusAI #EricLefkofsky #PrecisionMedicine #AIinHealthcare #Genomics #CancerResearch #DigitalHealth #HealthcareInnovation #BiotechPodcast #HealthTech #LifeSciences #DataDrivenMedicine #FutureofHealthcare
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
What if the secret engine driving modern drug discovery wasn’t in Boston or Basel, but in Shanghai? In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead dives deep into the rise of WuXi AppTec, a company that redefined how the world develops medicine.
We explore its fascinating journey, from a humble chemistry startup founded by Dr. Ge Li to a global R&D and manufacturing giant that helps nearly every top pharma and biotech company bring therapies to life. You’ll learn how WuXi pioneered the “R&D as a Service” model, bridged East and West in biotech innovation, and powered breakthroughs from cell and gene therapy to AI-driven drug design.
We also unpack its controversies, geopolitical challenges, and the lessons it offers about globalization, innovation, and resilience in today’s biotech landscape.
If you’ve ever wondered how new drugs move from an idea to reality and who’s quietly making it happen behind the scenes, this episode is for you.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#BiotechUnleashed #PetriDishPerspectives #WuXiAppTec #BiotechPodcast #DrugDiscovery #GlobalBiotech #CRO #PharmaInnovation #LifeSciences #BiotechChina #GeLi #PharmaPartnerships #HealthcareTransformation #MedicalInnovation
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
From a small pharmacy in Massachusetts to a $100 billion healthcare empire, CVS Health has redefined what it means to be a pharmacy. In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead dives into CVS’s fascinating evolution, from its early days as Consumer Value Store to its bold moves acquiring Aetna and transforming into a fully integrated healthcare provider.
We explore how CVS blended retail, insurance, and clinical services to build one of the most powerful healthcare ecosystems in the United States and how it continues to shape the future of accessible care through digital transformation, AI, and pharmacy innovation.
We uncover how a simple idea, providing affordable, convenient health access, turned into one of the most ambitious healthcare transformations of our time.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#CVSHealth #PetriDishPerspectives #BiotechUnleashed #HealthcareInnovation #PharmacyEvolution #Aetna #MinuteClinic #HealthTech #DigitalHealth #HealthcareStrategy #Manead #Podcast #BiotechStorytelling #HealthTransformation
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
From a lizard’s venom to Hollywood’s favorite weight-loss trend, this episode of Petri Dish Perspectives: Biotech Unleashed dives deep into the fascinating journey of GLP-1 agonists.Â
Discover how scientists uncovered a gut hormone that revolutionized diabetes care, led to the creation of Ozempic and Mounjaro, and sparked a cultural movement around body image and health. We’ll trace the science, the breakthroughs, and the billion-dollar race shaping the future of metabolic medicine.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#GLP1 #Ozempic #Mounjaro #Wegovy #BiotechUnleashed #PetriDishPerspectives #Biotech #Pharma #DrugDiscovery #Obesity #Diabetes #MetabolicHealth #HealthcareInnovation #SciencePodcast
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
From the publisher's feed
Burma | Chicago
Scientist 🥼🧪🔬
Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎
Stream new episodes every…
https://linktr.ee/maneadkhin
#biotech #pharma #healthcare #podcast #petridishperspectives